Abstract
There have been proposals that the tachykinin receptor classification should be extended to include a novel receptor, the “neurokinin-4” receptor (NK-4R), which has a close homology with the human NK-3 receptor (hNK-3R). We compared the pharmacological and molecular biological characteristics of the hNK-3R and NK-4R. Binding experiments, with 125I-[MePhe7]-NKB binding to HEK 293 cell membranes transiently expressing the hNK-3R (HEK 293-hNK-3R) or NK-4R (HEK 293-NK-4R), and functional studies (Ca2+ mobilization in the same cells) revealed a similar profile of sensitivity to tachykinin agonists and antagonists for both receptors; i.e., in binding studies with the hNK-3R, MePhe7-NKB > NKB > senktide ≫ NKA = Substance P; with the NK-4R, MePhe7-NKB > NKB = senktide ≫ Substance P = NKA; and with antagonists, SB 223412 = SR 142801 > SB 222200 ≫ SR 48968 ≫ CP 99994 for both hNK-3R and NK-4R. Thus, the pharmacology of the two receptors was nearly identical. However, attempts to isolate or identify the NK-4R gene by using various molecular biological techniques were unsuccessful. Procedures, including nested polymerase chain reaction studies, that used products with restriction endonuclease sites specific for either hNK-3R or NK-4R, failed to demonstrate the presence of NK-4R in genomic DNA from human, monkey, mouse, rat, hamster, or guinea pig, and in cDNA libraries from human lung, brain, or heart, whereas the hNK-3R was detectable in the latter libraries. In view of the failure to demonstrate the presence of the putative NK-4R it is thought to be premature to extend the current tachykinin receptor classification.
Footnotes
- Received February 29, 2000.
- Accepted May 26, 2000.
-
Send reprint requests to: Douglas W. P. Hay, Ph.D., Department of Pulmonary Biology, UW2532, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd., King of Prussia, PA 19406. E-mail:douglas_w_hay{at}sbphrd.com
-
↵1 Current address: Eli Lilly and Company, Research Technologies and Proteins, Lilly Corporation Center, Indianapolis, IN.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|